{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:02:30Z","timestamp":1792047750152,"version":"4.4.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T00:00:00Z","timestamp":1568937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009848","name":"Tower Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004802","name":"California Breast Cancer Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004802","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jsbmb.2019.105415","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T03:05:04Z","timestamp":1560913504000},"page":"105415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy"],"prefix":"10.1016","volume":"193","author":[{"given":"Diana C.","family":"M\u00e1rquez-Garb\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Begonya","family":"Comin-Anduix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro J.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanpeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Wang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gardenia","family":"Cheung-Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalo","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Pietras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9114","key":"10.1016\/j.jsbmb.2019.105415_bib0005","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jsbmb.2019.105415_bib0010","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1002\/cncr.23875","article-title":"Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions","volume":"113","author":"Hurvitz","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jsbmb.2019.105415_bib0015","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jsbmb.2019.105415_bib0020","article-title":"Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study","author":"Emens","year":"2018","journal-title":"JAMA Oncol."},{"issue":"22","key":"10.1016\/j.jsbmb.2019.105415_bib0025","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jsbmb.2019.105415_bib0030","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.mce.2013.06.003","article-title":"The immune system and inflammation in breast cancer","volume":"382","author":"Jiang","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1","key":"10.1016\/j.jsbmb.2019.105415_bib0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-16-0502","article-title":"Tumor cell-independent estrogen signaling drives disease progression through mobilization of myeloid-derived suppressor cells","volume":"7","author":"Svoronos","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.jsbmb.2019.105415_bib0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/2159-8290.CD-16-1308","article-title":"Repurposing antiestrogens for tumor immunotherapy","volume":"7","author":"Welte","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jsbmb.2019.105415_bib0045","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.3389\/fimmu.2018.02279","article-title":"Sex hormones in acquired immunity and autoimmune disease","volume":"9","author":"Moulton","year":"2018","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.jsbmb.2019.105415_bib0050","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.4049\/jimmunol.175.9.5716","article-title":"Estrogen receptor alpha (ERalpha) deficiency in macrophages results in increased stimulation of CD4+ T cells while 17beta-estradiol acts through ERalpha to increase IL-4 and GATA-3 expression in CD4+ T cells independent of antigen presentation","volume":"175","author":"Lambert","year":"2005","journal-title":"J. Immunol."},{"issue":"526","key":"10.1016\/j.jsbmb.2019.105415_bib0055","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aap9415","article-title":"Estrogen receptor alpha contributes to T cell-mediated autoimmune inflammation by promoting T cell activation and proliferation","volume":"11","author":"Mohammad","year":"2018","journal-title":"Sci. Signal."},{"issue":"9","key":"10.1016\/j.jsbmb.2019.105415_bib0060","doi-asserted-by":"crossref","first-page":"10557","DOI":"10.18632\/oncotarget.7235","article-title":"Activation of the PD-1\/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis","volume":"7","author":"Black","year":"2016","journal-title":"Oncotarget"},{"issue":"6382","key":"10.1016\/j.jsbmb.2019.105415_bib0065","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.jsbmb.2019.105415_bib0070","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-17-3452","article-title":"Safety and antitumor activity of Pembrolizumab in patients with estrogen receptor-positive\/human epidermal growth factor receptor 2-Negative advanced breast cancer","volume":"24","author":"Rugo","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.jsbmb.2019.105415_bib0075","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/annonc\/mdv192","article-title":"PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes","volume":"26","author":"Ali","year":"2015","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.jsbmb.2019.105415_bib0080","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1073\/pnas.1104303108","article-title":"Leukocyte composition of human breast cancer","volume":"109","author":"Ruffell","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.jsbmb.2019.105415_bib0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jsbmb.2019.105415_bib0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mce.2017.11.010","article-title":"Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer","volume":"466","author":"Boonyaratanakornkit","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"issue":"9472","key":"10.1016\/j.jsbmb.2019.105415_bib0095","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"E.B.C.T.C. Group","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jsbmb.2019.105415_bib0100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.clbc.2014.06.005","article-title":"A good drug made better: the fulvestrant dose-response story","volume":"14","author":"Robertson","year":"2014","journal-title":"Clin. Breast Cancer"},{"issue":"9453","key":"10.1016\/j.jsbmb.2019.105415_bib0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.jsbmb.2019.105415_bib0110","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1158\/1078-0432.CCR-07-1373","article-title":"Membrane-associated estrogen receptor signaling pathways in human cancers","volume":"13","author":"Pietras","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.jsbmb.2019.105415_bib0115","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.jsbmb.2019.105415_bib0120","first-page":"1244","article-title":"An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer","volume":"57","author":"Zhang","year":"1997","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.jsbmb.2019.105415_bib0125","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1021\/jm100047k","article-title":"Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs)","volume":"53","author":"Kieser","year":"2010","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.jsbmb.2019.105415_bib0130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1677\/joe.0.0990447","article-title":"Comparison of the biological effects of tamoxifen and a new antioestrogen (LY 117018) on the immature rat uterus","volume":"99","author":"Wakeling","year":"1983","journal-title":"J. Endocrinol."},{"issue":"38","key":"10.1016\/j.jsbmb.2019.105415_bib0135","doi-asserted-by":"crossref","first-page":"35684","DOI":"10.1074\/jbc.M101097200","article-title":"The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators","volume":"276","author":"Wijayaratne","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.jsbmb.2019.105415_bib0140","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-14-0697","article-title":"Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer","volume":"5","author":"van Kruchten","year":"2015","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.jsbmb.2019.105415_bib0145","article-title":"Evaluating an ER degrader for breast cancer","volume":"5","year":"2015","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.jsbmb.2019.105415_bib0150","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1021\/acs.jmedchem.5b00054","article-title":"Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts","volume":"58","author":"Lai","year":"2015","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.jsbmb.2019.105415_bib0155","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1021\/ol802328n","article-title":"A short, scalable synthesis of the carbocyclic core of the anti-angiogenic cortistatins from (+)-estrone by B-ring expansion","volume":"10","author":"Kurti","year":"2008","journal-title":"Org. Lett."},{"issue":"10","key":"10.1016\/j.jsbmb.2019.105415_bib0160","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1021\/jm0204340","article-title":"Synthesis and evaluation of B-, C-, and D-ring-substituted estradiol carboxylic acid esters as locally active estrogens","volume":"46","author":"Labaree","year":"2003","journal-title":"J. Med. Chem."},{"issue":"36","key":"10.1016\/j.jsbmb.2019.105415_bib0165","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1016\/j.tetlet.2006.06.136","article-title":"An environmentally friendly and cost effective synthesis of estradiol featuring two novel reagents: Si(0)\/KF and PMHS\/hexamethyldisiloxane\/pTSA","volume":"47","author":"Lim","year":"2006","journal-title":"Tetrahedron Lett."},{"issue":"16","key":"10.1016\/j.jsbmb.2019.105415_bib0170","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1021\/jo00121a061","article-title":"Novel stereoselective synthesis of 11.beta.-Carbon-Substituted estradiol derivatives","volume":"60","author":"Tedesco","year":"1995","journal-title":"J. Org. Chem."},{"issue":"1-2","key":"10.1016\/j.jsbmb.2019.105415_bib0175","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.mce.2005.11.020","article-title":"Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer","volume":"246","author":"Marquez","year":"2006","journal-title":"Mol. Cell. Endocrinol."},{"issue":"39","key":"10.1016\/j.jsbmb.2019.105415_bib0180","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1038\/sj.onc.1204729","article-title":"Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells","volume":"20","author":"Marquez","year":"2001","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.jsbmb.2019.105415_bib0185","first-page":"2435","article-title":"HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells","volume":"10","author":"Pietras","year":"1995","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.jsbmb.2019.105415_bib0190","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10549-010-1072-z","article-title":"Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells","volume":"128","author":"Berstein","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.jsbmb.2019.105415_bib0195","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1210\/en.2002-220620","article-title":"Elevated levels of epidermal growth factor receptor\/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells","volume":"144","author":"Knowlden","year":"2003","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.jsbmb.2019.105415_bib0200","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12020-009-9154-6","article-title":"Estrogen modulates expression of putative housekeeping genes in the mouse uterus","volume":"35","author":"Schroder","year":"2009","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.jsbmb.2019.105415_bib0205","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1021\/bi00726a019","article-title":"Preparation and characterization of free cell suspensions from the immature rat uterus","volume":"12","author":"Williams","year":"1973","journal-title":"Biochemistry"},{"issue":"12","key":"10.1016\/j.jsbmb.2019.105415_bib0210","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.bcp.2011.08.026","article-title":"Generation of stable reporter breast cancer cell lines for the identification of ER subtype selective ligands","volume":"82","author":"Shanle","year":"2011","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.jsbmb.2019.105415_bib0215","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/toxsci\/kfh180","article-title":"Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists","volume":"81","author":"Wilson","year":"2004","journal-title":"Toxicol. Sci."},{"issue":"24","key":"10.1016\/j.jsbmb.2019.105415_bib0220","doi-asserted-by":"crossref","first-page":"11287","DOI":"10.1158\/0008-5472.CAN-05-2737","article-title":"Aromatase inhibitors in human lung cancer therapy","volume":"65","author":"Weinberg","year":"2005","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jsbmb.2019.105415_bib0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4049\/jimmunol.1701494","article-title":"A beginner\u2019s guide to analyzing and visualizing mass cytometry data","volume":"200","author":"Kimball","year":"2018","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.jsbmb.2019.105415_bib0230","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nmeth.3863","article-title":"Automated mapping of phenotype space with single-cell data","volume":"13","author":"Samusik","year":"2016","journal-title":"Nat. Methods"},{"issue":"9","key":"10.1016\/j.jsbmb.2019.105415_bib0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005112","article-title":"Cytofkit: a bioconductor package for an integrated mass cytometry data analysis pipeline","volume":"12","author":"Chen","year":"2016","journal-title":"PLoS Comput. Biol."},{"issue":"6","key":"10.1016\/j.jsbmb.2019.105415_bib0240","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.jsbmb.2019.105415_bib0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012711","article-title":"Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma","volume":"5","author":"Comin-Anduix","year":"2010","journal-title":"PLoS One"},{"issue":"279","key":"10.1016\/j.jsbmb.2019.105415_bib0250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4691","article-title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma","volume":"7","author":"Hu-Lieskovan","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"Part I","key":"10.1016\/j.jsbmb.2019.105415_bib0255","first-page":"110","article-title":"New Estrogen Receptor Down-regulators to Treat Human Breast Cancer","volume":"31","author":"M.-G.D","year":"2016","journal-title":"Proceedings of the American Association for the Advancement of Science, Pacific Division"},{"issue":"3-8","key":"10.1016\/j.jsbmb.2019.105415_bib0260","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0960-0760(92)90392-V","article-title":"11 beta-amidoalkyl estradiols, a new series of pure antiestrogens","volume":"41","author":"Claussner","year":"1992","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"12","key":"10.1016\/j.jsbmb.2019.105415_bib0265","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1016\/j.bmc.2012.04.041","article-title":"Synthesis and evaluation of 11\u03b2-(4-substituted phenyl) estradiol analogs: transition from estrogen receptor agonists to antagonists","volume":"20","author":"Hanson","year":"2012","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.jsbmb.2019.105415_bib0270","first-page":"691","article-title":"Corrigendum: full antagonism of the estrogen receptor without a prototypical ligand side chain","volume":"13","author":"Srinivasan","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jsbmb.2019.105415_bib0275","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1248\/cpb.36.1529","article-title":"A, studies of reduction with the sodium borohydride-transition metal boride system. I.: reduction of nitro and the other functional groups with the sodium borohydride-nickel boride system","volume":"36","author":"Nose","year":"1988","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.jsbmb.2019.105415_bib0280","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1016\/S0040-4039(00)99014-2","article-title":"Rapid and efficient reduction of aliphatic nitro compounds to amines","volume":"26","author":"Osby JO","year":"1985","journal-title":"Tetrahedron Lett."},{"issue":"4","key":"10.1016\/j.jsbmb.2019.105415_bib0285","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00018-017-2686-7","article-title":"CD4 and CD8 T lymphocyte interplay in controlling tumor growth","volume":"75","author":"Ostroumov","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"issue":"5","key":"10.1016\/j.jsbmb.2019.105415_bib0290","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"29","key":"10.1016\/j.jsbmb.2019.105415_bib0295","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1200\/JCO.2009.27.2146","article-title":"Immune regulation of cancer","volume":"28","author":"Disis","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jsbmb.2019.105415_bib0300","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1210\/en.2018-00824","article-title":"17beta-estradiol and 17alpha-Ethinyl estradiol exhibit immunologic and epigenetic regulatory effects in NZB\/WF1 female mice","volume":"160","author":"Dai","year":"2019","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.jsbmb.2019.105415_bib0305","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jsbmb.2019.105415_bib0310","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4049\/jimmunol.1200266","article-title":"The indispensable role of CCR5 for in vivo suppressor function of tumor-derived CD103+ effector\/memory regulatory T cells","volume":"189","author":"Chang","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.jsbmb.2019.105415_bib0315","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fimmu.2012.00274","article-title":"Regulatory dendritic cells: there is more than just immune activation","volume":"3","author":"Schmidt","year":"2012","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jsbmb.2019.105415_bib0320","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: in vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2019.105415_bib0325","doi-asserted-by":"crossref","first-page":"13","DOI":"10.12703\/P6-13","article-title":"The M1 and M2 paradigm of macrophage activation: time for reassessment","volume":"6","author":"Martinez","year":"2014","journal-title":"F1000Prime Rep."},{"key":"10.1016\/j.jsbmb.2019.105415_bib0330","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3389\/fimmu.2018.00552","article-title":"Sexual dimorphism of immune responses: a new perspective in Cancer immunotherapy","volume":"9","author":"Capone","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jsbmb.2019.105415_bib0335","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3109\/08830185.2015.1018417","article-title":"Sex-driven differences in immunological responses: challenges and opportunities for the immunotherapies of the third millennium","volume":"34","author":"Mirandola","year":"2015","journal-title":"Int. Rev. Immunol."},{"issue":"19","key":"10.1016\/j.jsbmb.2019.105415_bib0340","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1158\/0008-5472.CAN-18-1229","article-title":"Inhibition of casein kinase 2 disrupts differentiation of myeloid cells in cancer and enhances the efficacy of immunotherapy in mice","volume":"78","author":"Hashimoto","year":"2018","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.jsbmb.2019.105415_bib0345","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cellsig.2016.03.007","article-title":"Estrogen receptor alpha transcriptionally activates casein kinase 2 alpha: a pivotal regulator of promyelocytic leukaemia protein (PML) and AKT in oncogenesis","volume":"28","author":"Das","year":"2016","journal-title":"Cell. Signal."},{"issue":"5","key":"10.1016\/j.jsbmb.2019.105415_bib0350","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1189\/jlb.1HI1016-306RR","article-title":"Frontline Science: myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice","volume":"101","author":"Ostrand-Rosenberg","year":"2017","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"10.1016\/j.jsbmb.2019.105415_bib0355","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1189\/jlb.1A1015-481RR","article-title":"Myeloid-derived suppressor cells are essential for maintaining feto-maternal immunotolerance via STAT3 signaling in mice","volume":"100","author":"Pan","year":"2016","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.jsbmb.2019.105415_bib0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"19","key":"10.1016\/j.jsbmb.2019.105415_bib0365","doi-asserted-by":"crossref","first-page":"17462","DOI":"10.18632\/oncotarget.3958","article-title":"CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.jsbmb.2019.105415_bib0370","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","article-title":"Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression","volume":"22","author":"Ostrand-Rosenberg","year":"2012","journal-title":"Semin. Cancer Biol."},{"issue":"6230","key":"10.1016\/j.jsbmb.2019.105415_bib0375","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"20","key":"10.1016\/j.jsbmb.2019.105415_bib0380","doi-asserted-by":"crossref","first-page":"32536","DOI":"10.18632\/oncotarget.15812","article-title":"Immunotherapeutic target expression on breast tumors can be amplified by hormone receptor antagonism: a novel strategy for enhancing efficacy of targeted immunotherapy","volume":"8","author":"Jaini","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jsbmb.2019.105415_bib0385","first-page":"1","article-title":"Expression of programed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol","author":"Wu","year":"2018","journal-title":"Gynecol. Endocrinol."},{"issue":"2","key":"10.1016\/j.jsbmb.2019.105415_bib0390","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/IGC.0000000000000875","article-title":"Posttranscriptional control of PD-L1 expression by 17beta-Estradiol via PI3K\/Akt signaling pathway in ERalpha-positive cancer cell lines","volume":"27","author":"Yang","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.jsbmb.2019.105415_bib0395","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/intimm\/dxl151","article-title":"Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1)","volume":"19","author":"Polanczyk","year":"2007","journal-title":"Int. Immunol."},{"issue":"2","key":"10.1016\/j.jsbmb.2019.105415_bib0400","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/aji.12532","article-title":"Menopausal status influences the expression of programmed death (PD)-1 and its ligand PD-L1 on immune cells from the human female reproductive tract","volume":"76","author":"Shen","year":"2016","journal-title":"Am. J. Reprod. Immunol."},{"issue":"21","key":"10.1016\/j.jsbmb.2019.105415_bib0405","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jsbmb.2019.105415_bib0410","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cellimm.2015.01.018","article-title":"Estrogen receptors regulate innate immune cells and signaling pathways","volume":"294","author":"Kovats","year":"2015","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jsbmb.2019.105415_bib0415","article-title":"Arrested developments: CDK4\/6 inhibitor resistance and alterations in the tumor immune microenvironment","author":"Teh","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.jsbmb.2019.105415_bib0420","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"A selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res."},{"issue":"5","key":"10.1016\/j.jsbmb.2019.105415_bib0425","first-page":"381","article-title":"Cell cycle control by steroid hormones","volume":"5","author":"Musgrove","year":"1994","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.jsbmb.2019.105415_bib0430","doi-asserted-by":"crossref","first-page":"6924","DOI":"10.18632\/oncotarget.24023","article-title":"ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models","volume":"9","author":"Guo","year":"2018","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.jsbmb.2019.105415_bib0435","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1158\/1078-0432.CCR-15-0360","article-title":"Efficacy of SERD\/SERM Hybrid-CDK4\/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer","volume":"21","author":"Wardell","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.jsbmb.2019.105415_bib0440","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/0008-5472.CAN-15-2357","article-title":"AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models","volume":"76","author":"Weir","year":"2016","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.jsbmb.2019.105415_bib0445","doi-asserted-by":"crossref","first-page":"E3673","DOI":"10.1073\/pnas.1803291115","article-title":"Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis","volume":"115","author":"Zhao","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076019300366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076019300366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:01:51Z","timestamp":1760745711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076019300366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":89,"alternative-id":["S0960076019300366"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2019.105415","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2019.105415","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105415"}}